Eiger Biopharmaceuticals
Santa Clara, US · Delaware corporation · 3 known investors
Biotech
Founders & leadership
JG
Jeffrey GlennNamed on SEC filing
DC
David CoryNamed on SEC filing
Board
NK
EE
Ed EnglemanBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$20.5M disclosed across 2 rounds · 2011–2015
▶$6MraisedNov 2015 · 4 investors · BiotechnologyRule 506(b)
▶$6MraisedNov 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas DietzDirector
- David CoryExecutive Officer, Director
- Nina KjellsonDirector
- Ed EnglemanDirector
- Jeffrey GlennDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedMar 2015 · 8 investors · BiotechnologyRule 506(b)
▶$14.5MraisedMar 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nina KjellsonDirector
- Ed EnglemanDirector
- Jeffrey GlennDirector
- David CoryExecutive Officer, Director
- Offering amount
- $14.6M
- Amount sold
- $14.5M
- First sale
- Apr 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Eiger Biopharmaceuticals's investors?
- Eiger Biopharmaceuticals's investors include Pfizer Venture Investments, Canaan Partners, Vivo Capital.
- How much funding has Eiger Biopharmaceuticals raised?
- Eiger Biopharmaceuticals has disclosed $20.5M raised across 2 rounds.
- Where is Eiger Biopharmaceuticals headquartered?
- Eiger Biopharmaceuticals is headquartered in Santa Clara, US.